Acute Myeloid Leukemia
Nancy Simonian, MD, discusses the results at ASH 2018.
Joshua Zeidner, MD, discusses stage 1 findings at the ASH 2018 meeting.
Rod A. Humerickhouse, MD, PhD, discusses findings from AbbVie at the ASH 2018 meeting.
No Survival Benefit Found With Allogeneic Hematopoietic Cell Transplantation in Older Patients With AMLDecember 01, 2018
At first glance, the data on 695 patients with advanced myeloid leukemia (AML) seem to support a survival advantage of allogeneic hematopoietic cell transplantation (HCT) compared with no transplantation.
There were no previously unknown AML-specific mutations or structural variations in immune-related genes among patients with AML who had undergone transplant.
In mice models, the systemic delivery of blood platelets that were coated with anti-PD-1 antibodies and conjugated to HSCs halted the recurrence of leukemia.
There were 11 genes identified in BeatAML — called in at least 1% of patients — that were not originally recognized in previous AML sequencing studies.
Quizartinib — an investigational FLT3 inhibitor — is the first agent in its class to demonstrate improved overall survival.
Ivosidenib is the first-in-class FDA approval for IDH1 mutation-harboring acute myeloid leukemia.
Individuals at high risk of developing AML can be identified years before symptoms appear, a new study reports.
Investigators sought to evaluate the efficacy of enasidenib among older patients with untreated acute myeloid leukemia, a population that is associated with poor therapeutic outcomes.
The effect of CAR-T therapy in acute myeloid leukemia has yet to be fully explored.
Researchers determined 3 levels of somatic mutation clearance based on VAF of residual mutations at CR.
Findings from previous studies suggests that multiparameter flow cytometric minimal residual disease may be used to predict outcomes in acute myeloid leukemia.
The most frequently observed adverse events among patients treated with sorafenib were cytopenias and skin rashes.
Previous studies showed that romiplostim for thrombocytopenia in MDS improved hematologic outcomes but may increase the risk of AML.
The risk of AML decreased after 2 years, returning to baseline within 6 years of WDTC diagnosis, but the risk of CML remained elevated for up to 10 years.
Researchers randomly assigned 597 patients with newly diagnosed AML to receive intermediate- or conventional-dose cytarabine plus homoharringtonine and daunorubicin.
At the end of maintenance, 57% and 64% of patients remained in the midostaurin arm or the placebo arm, respectively. There were 16 relapse events after maintenance in the midostaurin arm and 7 relapses and 2 deaths in the placebo arm.
Elias Jabbour, MD, discusses the latest developments in the treatment of acute and chronic leukemia from the ASH 2017 meeting.
For a meta-analysis, researchers evaluated outcomes data from 9 studies consisting of 6762 patients with an acute leukemia to determine whether HSCT is superior to UCBT.
Gilteritinib inhibits the FLT3 mutations observed in up to one-third of patients with AML, FLT3 internal tandem duplication, and the FLT3 tyrosine kinase domain.
Standard cytotoxic chemotherapy remains the standard treatment for AML, though a large proportion of patients relapse and/or develop resistance to conventional therapy, indicating a need for new treatments.
Researchers analyzed human AML samples to determine potential selective targets in leukemia stem cells, the source of resistance to standard chemotherapy.
Guadecitabine, a next-generation hypomethylating agent, has been shown to have a longer half-life and to prolong periods of exposure more than its predecessors.
Among patients with R/R disease, 19.3% achieved complete remission (CR) and had a median overall survival of 19.7 months.
Approval was based on data from a randomized phase 3 trial in which researchers compared the efficacy of the daunorubicin-cytarabine combination with that of a standard regimen.
The US Food and Drug Administration approved enasidenib for the treatment of adult patients with relapsed or refractory AML with an IDH2 mutation.
The US Food and Drug Administration granted orphan drug designation to gilteritinib for the treatment of AML.
Adding midostaurin — a multi-targeted kinase inhibitor — to chemotherapy prolongs overall survival (OS) among patients with newly diagnosed AML and an FLT3 mutation.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Daratumumab Combination: New Standard of Care in Transplant-Ineligible Multiple Myeloma
- Adjuvant Trastuzumab Emtansine Confers Improved Outcome in KATHERINE Trial
- Extension of Adjuvant Anastrozole Regimen to 10 Years Yields Higher DFS, but Not OS
- Changes in Renal Cell Carcinoma Pathologic Staging and Histologic Grading
- Study Identifies Patients With Breast Cancer Who Don't Benefit From Adjuvant Chemo
- CD19 CAR T-Cell Therapies: "Expect an Evolution"
- Hypofractionated WBI Found Noninferior to Conventionally Fractionated WBI
- Selinexor Trials Move Nuclear Suppressor Protein-Export Inhibition Closer to the Clinic for Multiple Myeloma
- Younger Breast Cancer Patients at Higher Risk for Osteoporosis
- Molecular Mechanisms Underlying Immunosurveillance in Multiple Myeloma Identified